Regulatory role of c-Met in insulin-like growth factor-I receptor–mediated migration and invasion of human pancreatic carcinoma cells

Pancreatic carcinoma cells overexpress the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and the hepatocyte growth factor (HGF) receptor, c-Met, which are both known to mediate tumor cell migration and invasion. We hypothesized that IGF-IR and c-Met cooperate to induce migration and invasion of human pancreatic carcinoma cells and that IGF-I-mediated migration and invasion depend on c-Met. Migration and invasion assays were done with the human pancreatic cancer cell line L3.6pl treated with PBS, IGF-I, HGF, or IGF-I plus HGF. To determine if c-Met is necessary for IGF-IR-mediated migration and invasion, c-Met was down-regulated in L3.6pl cells via adenoviral infection with a c-Met ribozyme before IGF-I treatment. IGF-I and HGF increased cell migration and invasion. Furthermore, IGF-I plus HGF had a greater than additive effect on cell migration and invasion compared with either growth factor alone. Down-regulation of c-Met nearly completely inhibited IGF-I-mediated migration and invasion. Our findings suggest that IGF-IR and c-Met cooperate to induce migration and invasion of human pancreatic carcinoma cells. Furthermore, c-Met is required for both HGF- and IGF-I-mediated migration and invasion. Elucidation of the signaling pathways that contribute to tumor progression and metastasis should provide a foundation for the development of targeted therapies for pancreatic carcinoma. [Mol Cancer Ther 2006;5(7):1676–82]

[1]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[2]  E. Lengyel,et al.  Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor* , 1999, The Journal of Biological Chemistry.

[3]  S. Curley,et al.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. , 1993, The Journal of clinical investigation.

[4]  L. Ellis,et al.  Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  C. Mantzoros,et al.  The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications , 2002, Oncology.

[6]  S. Korsmeyer,et al.  Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.

[7]  J. McCarthy,et al.  Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation. , 2003, Experimental cell research.

[8]  M. Karas,et al.  The Potentiation of Estrogen on Insulin-like Growth Factor I Action in MCF-7 Human Breast Cancer Cells Includes Cell Cycle Components* , 2000, The Journal of Biological Chemistry.

[9]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[10]  S. Goodman,et al.  Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 Patients , 1995, Annals of surgery.

[11]  J. C. Barrett,et al.  Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? , 2003, Molecular cancer research : MCR.

[12]  T. Nakamura,et al.  Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. , 1998, The American journal of pathology.

[13]  L. Liotta,et al.  The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. , 1989, The Journal of biological chemistry.

[14]  C. Kahn,et al.  Gab-1-mediated IGF-1 Signaling in IRS-1-deficient 3T3 Fibroblasts* , 2000, The Journal of Biological Chemistry.

[15]  L. Ellis,et al.  Impact of Insulin-Like Growth Factor Receptor-I Function on Angiogenesis, Growth, and Metastasis of Colon Cancer , 2002, Laboratory Investigation.

[16]  H. Yeger,et al.  Expression and localization of HGF and met in Wilms' tumours , 2002, The Journal of pathology.

[17]  T. Matsuyama,et al.  Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation , 2001, Oncogene.

[18]  B. Peace,et al.  Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. , 2003, Experimental cell research.

[19]  Lee M Ellis,et al.  Insulinlike Growth Factor-I–Mediated Migration and Invasion of Human Colon Carcinoma Cells Requires Activation of c-Met and Urokinase Plasminogen Activator Receptor , 2005, Annals of surgery.

[20]  L. Ellis,et al.  Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. , 2003, The American journal of pathology.

[21]  G. V. Vande Woude,et al.  HGF/SF‐met signaling in the control of branching morphogenesis and invasion , 2003, Journal of cellular biochemistry.

[22]  S. Cianfarani,et al.  IGF-I stimulates chemotaxis of human neuroblasts. Involvement of type 1 IGF receptor, IGF binding proteins, phosphatidylinositol-3 kinase pathway and plasmin system. , 2000, The Journal of endocrinology.

[23]  J. Oh,et al.  Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. , 2001, Cancer research.

[24]  C. Roberts,et al.  The insulin-like growth factor system and cancer. , 2003, Cancer letters.

[25]  Y. Wong,et al.  Aberrant expression of hepatocyte growth factor and its receptor, c-Met, during sex hormone-induced prostatic carcinogenesis in the Noble rat. , 2000, Carcinogenesis.

[26]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[27]  L. Koniaris,et al.  Insulin‐like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma , 2002, Hepatology.

[28]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[29]  I. Fidler,et al.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. , 1999, Neoplasia.

[30]  T. Nielsen,et al.  Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival , 2004, Cancer Research.

[31]  K. Ohuchida,et al.  Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. , 2003, Cancer letters.

[32]  B. Zbar,et al.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. , 2002, The Journal of clinical investigation.

[33]  L. Ellis,et al.  Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. , 2003, Cancer research.

[34]  P. Vollenweider,et al.  Insulin and Insulin-like Growth Factor I Receptors Utilize Different G Protein Signaling Components* , 2001, The Journal of Biological Chemistry.

[35]  A. Barrier,et al.  [Pancreaticoduodenectomy for cancer of the head of the pancreas]. , 2008, Journal de chirurgie.

[36]  R. Salgia,et al.  Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  R. Radinsky,et al.  Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated β-catenin , 2004, Clinical & Experimental Metastasis.

[38]  H. Dietz,et al.  Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. , 1999, Journal of the National Cancer Institute.

[39]  W. Birchmeier,et al.  Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. , 1992, The EMBO journal.

[40]  Y. Maehara,et al.  Concurrent overexpression of ETS‐1 and C‐met correlates with a phenotype of high cellular motility in human esophageal cancer , 2002, International journal of cancer.

[41]  V. de Lédinghen,et al.  Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. , 1999, Journal of hepatology.

[42]  E. Karna,et al.  Serum and tissue level of insulin‐like growth factor‐I (IGF‐I) and IGF‐I binding proteins as an index of pancreatitis and pancreatic cancer , 2002, International journal of experimental pathology.

[43]  L. Tacchini,et al.  Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. , 2003, Experimental cell research.

[44]  J. Camonis,et al.  A PDZ Domain Protein Interacts with the C-terminal Tail of the Insulin-like Growth Factor-1 Receptor but Not with the Insulin Receptor* , 2001, The Journal of Biological Chemistry.

[45]  D. Carbone,et al.  Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. , 2003, Cancer research.